126 related articles for article (PubMed ID: 21454973)
1. Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.
Cereda S; Reni M; Rognone A; Fugazza C; Ghidini M; Ceraulo D; Brioschi M; Nicoletti R; Villa E
Chemotherapy; 2011; 57(2):156-61. PubMed ID: 21454973
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.
Lim KH; Kim TY; Lee KH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1017-26. PubMed ID: 21327930
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.
Reni M; Panucci MG; Passoni P; Bonetto E; Nicoletti R; Ronzoni M; Zerbi A; Staudacher C; Di Carlo V; Villa E
Cancer Invest; 2004; 22(5):688-96. PubMed ID: 15581049
[TBL] [Abstract][Full Text] [Related]
4. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
Pectasides D; Aravantinos G; Kalofonos H; Kiamouris C; Bafaloukos D; Xiros N; Nicolaides C; Visvikis A; Dimopoulos MA
Ann Oncol; 2001 Oct; 12(10):1417-22. PubMed ID: 11762814
[TBL] [Abstract][Full Text] [Related]
6. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V
Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.
Crinò L; Scagliotti GV; Ricci S; De Marinis F; Rinaldi M; Gridelli C; Ceribelli A; Bianco R; Marangolo M; Di Costanzo F; Sassi M; Barni S; Ravaioli A; Adamo V; Portalone L; Cruciani G; Masotti A; Ferrara G; Gozzelino F; Tonato M
J Clin Oncol; 1999 Nov; 17(11):3522-30. PubMed ID: 10550150
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel.
Polyzos A; Tsavaris N; Gogas H; Lagadas A; Polyzos K; Giannakopoulos K; Felekouras E; Tsigris C; Karatzas T; Papadopoulos O; Giannopoulos A
Anticancer Res; 2009 Jul; 29(7):2681-6. PubMed ID: 19596946
[TBL] [Abstract][Full Text] [Related]
9. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.
Fizazi K; Gravis G; Flechon A; Geoffrois L; Chevreau C; Laguerre B; Delva R; Eymard JC; Rolland F; Houede N; Laplanche A; Burcoveanu D; Culine S
Ann Oncol; 2014 May; 25(5):987-91. PubMed ID: 24595454
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Danson S; Middleton MR; O'Byrne KJ; Clemons M; Ranson M; Hassan J; Anderson H; Burt PA; Fairve-Finn C; Stout R; Dowd I; Ashcroft L; Beresford C; Thatcher N
Cancer; 2003 Aug; 98(3):542-53. PubMed ID: 12879472
[TBL] [Abstract][Full Text] [Related]
11. Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers.
Klapdor R; Seutter E; Lang-Pölckow EM; Reichle H; Hinrichs A
Anticancer Res; 1999; 19(4A):2459-69. PubMed ID: 10470175
[TBL] [Abstract][Full Text] [Related]
12. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.
Reni M; Pasetto L; Aprile G; Cordio S; Bonetto E; Dell'Oro S; Passoni P; Piemonti L; Fugazza C; Luppi G; Milandri C; Nicoletti R; Zerbi A; Balzano G; Di Carlo V; Brandes AA
Br J Cancer; 2006 Mar; 94(6):785-91. PubMed ID: 16508631
[TBL] [Abstract][Full Text] [Related]
13. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.
Kim JH; Lee SC; Oh SY; Song SY; Lee N; Nam EM; Lee S; Hwang IG; Lee HR; Lee KT; Bae SB; Kim HJ; Jang JS; Lim DH; Lee HW; Kang SY; Kang JH
Cancer Commun (Lond); 2018 Jun; 38(1):32. PubMed ID: 29866170
[TBL] [Abstract][Full Text] [Related]
14. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
Oh SY; Kim HJ; Kim TH; Lee GW; Kim HG; Jeong CY; Kwon HC; Kang JH
Invest New Drugs; 2010 Jun; 28(3):343-9. PubMed ID: 19444385
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
Piantedosi FV; Caputo F; Mazzarella G; Gilli M; Pontillo A; D'Agostino D; Campbell S; Marsico SA; Bianco A
Cancer Chemother Pharmacol; 2008 Apr; 61(5):803-7. PubMed ID: 17639396
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Reni M; Cereda S; Rognone A; Belli C; Ghidini M; Longoni S; Fugazza C; Rezzonico S; Passoni P; Slim N; Balzano G; Nicoletti R; Cappio S; Doglioni C; Villa E
Cancer Chemother Pharmacol; 2012 Jan; 69(1):115-23. PubMed ID: 21626049
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy].
Hu S; He X; Dong M; Jia B; Zhou S; Yang J; Yang S; Zhang C; Liu P; Qin Y; Gui L
Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):632-6. PubMed ID: 26714607
[TBL] [Abstract][Full Text] [Related]
20. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]